The Oxy’Pharm group wishes to provide its expertise in the field of hygiene by meeting the versatility needs of... View Article
Author Archives for Adeline Chauvigné
New member | Oxy’Pharm
1 July 2025The Oxy’Pharm group wishes to provide its expertise in the field of hygiene by meeting the versatility needs of... View Article
New member | SYMBIOTYC
SYMBIOTYC® provides its customers with more than 20 years of experience in the healthcare industry. It helps pharmaceutical, medical... View Article
New member | SYMBIOTYC
1 July 2025SYMBIOTYC® provides its customers with more than 20 years of experience in the healthcare industry. It helps pharmaceutical, medical... View Article
KetoM+ | The first product developed
FACILITATING ACCESS TO METABOLIC THERAPEUTIC DIET, HAS DEVELOPED ITS 1ST PRODUCT: A SPECIFIC GROUP FOOD (SGA). It is a formula... View Article
KetoM+ | The first product developed
1 July 2025FACILITATING ACCESS TO METABOLIC THERAPEUTIC DIET, HAS DEVELOPED ITS 1ST PRODUCT: A SPECIFIC GROUP FOOD (SGA). It is a formula... View Article
Launch of a healthcare science and innovation partnership between Philips and Rennes University Hopistal that is unique in France
To mark the launch of their science and innovation partnership, Rennes CHU and Philips have spotlighted three major focus... View Article
Launch of a healthcare science and innovation partnership between Philips and Rennes University Hopistal that is unique in France
1 July 2025To mark the launch of their science and innovation partnership, Rennes CHU and Philips have spotlighted three major focus... View Article
New member | IRICE
Jeanne Chamousset-Roman is Consultant in Regulatory Affairs and Quality Management in MEDICAL DEVICES supporting companies for various procedures: Regulatory... View Article
New member | IRICE
1 July 2025Jeanne Chamousset-Roman is Consultant in Regulatory Affairs and Quality Management in MEDICAL DEVICES supporting companies for various procedures: Regulatory... View Article
Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
Valneva, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced it is... View Article
Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
1 July 2025Valneva, a specialty vaccine company focused on prevention of infectious diseases with significant unmet medical need, today announced it is... View Article
Valneva Reports FY 2020 Cash of Over €200 Million
FY 2020 cash and cash equivalents of €204.4 million, exceeding guidance of between €180 million and €200 million. FY 2020... View Article
Valneva Reports FY 2020 Cash of Over €200 Million
1 July 2025FY 2020 cash and cash equivalents of €204.4 million, exceeding guidance of between €180 million and €200 million. FY 2020... View Article
New member | MAD-UP
MAD-UP specializes in the development of technological solutions for the health care of musculoskeletal disorders. Its intelligent dynamic compression solution... View Article
New member | MAD-UP
1 July 2025MAD-UP specializes in the development of technological solutions for the health care of musculoskeletal disorders. Its intelligent dynamic compression solution... View Article
GlioCure announces that it has been granted patent protection of its drug candidate GC01 in India
GlioCure SAS, a biotechnology company specialised in neuro-oncology, announced that it has been granted an Indian patent for its drug... View Article
GlioCure announces that it has been granted patent protection of its drug candidate GC01 in India
1 July 2025GlioCure SAS, a biotechnology company specialised in neuro-oncology, announced that it has been granted an Indian patent for its drug... View Article
OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011
OSE Immunotherapeutics today announced enrolment of the first patient in its Phase 2 clinical trial evaluating the benefits of anti-IL-7... View Article
OSE Immunotherapeutics Announces Enrolment of First Patient with Ulcerative Colitis in Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011
1 July 2025OSE Immunotherapeutics today announced enrolment of the first patient in its Phase 2 clinical trial evaluating the benefits of anti-IL-7... View Article